An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

Inclusion Criteria

• •Diagnosis of drug-resistant epilepsy
• •Patients who experience multiple episodes of acute repetitive seizures requiring at least one concomitant antiepileptic drug (AED)
• •Occurrence of at least 3 seizure clusters within the past 12 months, including at least one cluster in the 4 months prior to the Screening Visit
• •A caregiver must consent to participate together with the subject for purposes of observation and data collection
• •The caregiver must be present when the investigational product is administered
• •Screening body weight between 26 to 111 kg, inclusive